Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib and Divalproex Sodium in Advanced Solid Tumors
NCT03919292Phase 2Suspended
- Sponsor
- Virginia Commonwealth University
- Start
- May 2019
- Primary completion
- Dec 2029
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2 trial of neratinib and divalproex sodium in solid tumor, colon cancer, glioblastoma (GBM) and 2 more (6 arms), sponsored by Virginia Commonwealth University. Primary endpoint: Recommended Phase 2 Dose at 28 Days. Started May 2019; status: suspended.
02
Drugs
neratinibdivalproex sodium
03
Conditions
solid tumorcolon cancerglioblastoma (GBM)Ocular melanoma (OM)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03919292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03919292.